A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multiple Myeloma
ENROLLING
Trial ID:
NCT05535244 Protocol # :
23-057
Phase
I/II
Disease Sites
Multiple Myeloma
Principal Investigator
Midha, Shonali
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #23-057
23-057